Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 7 results
Author
Title
Type
[
Year
]
Filters:
Keyword
is
Crohn Disease
and
Author
is
Simpson, Kenneth W
[Clear All Filters]
2007
Baumgart M
,
Dogan B
,
Rishniw M
,
Weitzman G
,
Bosworth B
,
Yantiss R
,
Orsi RH
,
Wiedmann M
,
McDonough P
,
Kim SGuk
et al.
. 2007.
Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.
.
ISME J. 1(5):403-18.
2012
Craven M
,
Egan CE
,
Dowd SE
,
McDonough SP
,
Dogan B
,
Denkers EY
,
Bowman D
,
Scherl EJ
,
Simpson KW
. 2012.
Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease.
.
PLoS One. 7(7):e41594.
2013
Dogan B
,
Scherl E
,
Bosworth B
,
Yantiss R
,
Altier C
,
McDonough PL
,
Jiang Z-D
,
Dupont HL
,
Garneau P
,
Harel J
et al.
. 2013.
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.
.
Inflamm Bowel Dis. 19(1):141-50.
Kothary V
,
Scherl EJ
,
Bosworth B
,
Jiang Z-D
,
Dupont HL
,
Harel J
,
Simpson KW
,
Dogan B
. 2013.
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
.
Antimicrob Agents Chemother. 57(2):811-7.
2014
Dogan B
,
Suzuki H
,
Herlekar D
,
R Sartor B
,
Campbell BJ
,
Roberts CL
,
Stewart K
,
Scherl EJ
,
Araz Y
,
Bitar PP
et al.
. 2014.
Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.
.
Inflamm Bowel Dis. 20(11):1919-32.
2017
Viladomiu M
,
Kivolowitz C
,
Abdulhamid A
,
Dogan B
,
Victorio D
,
Castellanos JG
,
Woo V
,
Teng F
,
Tran NL
,
Sczesnak A
et al.
. 2017.
IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.
.
Sci Transl Med. 9(376)
2018
Dogan B
,
Fu J
,
Zhang S
,
Scherl EJ
,
Simpson KW
. 2018.
Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.
.
J Antibiot (Tokyo). 71(5):485-494.